This article is more than 5 years old. Information may no longer be current.

FDA approves generic levofloxacin ophthalmic solution

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

AMITYVILLE, N.Y. — The U.S. Food and Drug Administration has granted Hi-Tech Pharmacal final approval to market levofloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis, the company announced in a press release.

Hi-Tech plans to launch the drug, the generic equivalent of Quixin (levofloxacin ophthalmic solution 0.5%, Vistakon), next month.

Currently, Hi-Tech has 15 products awaiting FDA approval, the release said.